Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month High - Still a Buy?

Key Points

• Supernus Pharmaceuticals reached a new 52-week high of $46.58 during trading, with a notable trading volume of 58,918 shares.
• Analysts have increased their price targets for Supernus, with an average target of $43.00, and ratings varying from "buy" to "hold".
• Recent insider trading saw significant sales, with 179,606 shares sold over the last 90 days, indicating possible shifts in investor confidence.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $46.40 and last traded at $46.58, with a volume of 58918 shares changing hands. The stock had previously closed at $46.00.

Analyst Upgrades and Downgrades

Several equities analysts have commented on SUPN shares. Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a report on Wednesday, August 6th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Piper Sandler lifted their price target on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday, August 29th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Stock Performance

The stock has a market capitalization of $2.55 billion, a P/E ratio of 39.53 and a beta of 0.79. The stock's fifty day simple moving average is $39.42 and its two-hundred day simple moving average is $34.58.

Insider Transactions at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 140,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total value of $5,882,800.00. Following the transaction, the chief executive officer owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. The trade was a 11.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frederick M. Hudson sold 7,457 shares of the business's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares in the company, valued at $1,956,933.82. This trade represents a 13.87% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 241,506 shares of company stock worth $10,466,794. Company insiders own 8.80% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after purchasing an additional 1,083 shares during the period. Two Sigma Advisers LP lifted its position in shares of Supernus Pharmaceuticals by 14.7% during the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock valued at $282,000 after acquiring an additional 1,000 shares during the period. Principal Financial Group Inc. lifted its position in shares of Supernus Pharmaceuticals by 3.2% during the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after acquiring an additional 9,590 shares during the period. SG Americas Securities LLC lifted its position in shares of Supernus Pharmaceuticals by 63.6% during the 1st quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after acquiring an additional 6,867 shares during the period. Finally, Quantinno Capital Management LP lifted its position in shares of Supernus Pharmaceuticals by 11.5% during the 4th quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after acquiring an additional 864 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.